Prostaglandins (PGs) are known to have effects on hepatic glucose metabolism. Some actions of PGs in intact liver systems may not involve PG effects directly at the level of the hepatocyte. To define the ability of structurally distinct prostaglandins to affect hepatocyte metabolism directly, the regulation of glycogenolysis was studied in hepatocytes isolated from male Sprague-Dawley rats. PGF2, and PGB2 inhibited glucagon-stimulated glycogenolysis in the hepatocyte system. Pinane thromboxane A2 (PTA2) and PGD2 had no effect on glucagon-stimulated glycogenolysis.
INTRODUCTION
Several laboratories have reported effects of prostaglandins (PGs) on liver glycogenolysis and glucose production [1] [2] [3] [4] [5] [6] [7] [8] [9] . However, conflicting conclusions have been reported as to whether a specific PG causes stimulation, inhibition, or has no effect on hepatic glucose release. For example, PGE has been reported to stimulate glucose production in the perfused liver [5] [6] [7] , whereas other laboratories have reported inhibition of hormone-stimulated glycogenolysis in isolated hepatocytes [4, 9] . These observations may not be contradictory, as the perfused liver contains multiple cell types, and indirect effects of an intervention on hepatocyte metabolism are possible. The vasculature remains functional in the perfused liver, and changes in vascular tone result in altered perfusion pressures and flow, which in turn alter hepatocyte metabolism [6, 10] . For PGs, which are vasoactive, the differentiation is important, as PGs are not circulating hormones, but act locally. Therefore introduction of high concentrations of PGs into the perfusate of a perfused liver system is non-physiological.
Studies using the perfused liver system have suggested that a variety of hormones, drugs and other substances can alter PG production by the liver [1 1-13] . This PG production by the liver has been suggested to mediate the effects of platelet-activating factor [12] , phorbol esters [11, 13] and other substances [6, 14] [16] . Hepatocytes prepared by this method maintain hormonal responsiveness [4, 16] and PG-binding properties [17] . Hepatocytes used in the current studies contained 2.81 + 0.16 mg of protein/106 cells (n = 32), had a wet weight of 14.0+0.8 mg/106 cells (n = 26) and were 94+1% (n = 36) viable, based on Trypan Blue exclusion.
Liver plasma membranes were isolated from rats (244 +8 g; n = 20) by the sucrose-gradient technique of Smigel & Fleischer [18] as previously described [17] . Membranes were frozen at -70°C until used in the adenylate cyclase assay.
Hepatocyte incubations
Incubations were conducted in 25 ml Erlenmeyer flasks at 37°C under 02/C02 
RESULTS
The effects of distinct PGs on glucagon-stimulated glycogenolysis and cyclic AMP accumulation in the hepatocyte system were initially studied (Table 1) . Glucagon (0.5 /sM) increased glucose production and cyclic AMP accumulation, and PGF2, and PGB2 (each at 1 /sM) inhibited glucagon-stimulated glyco- PGF2 also inhibited glucagon-stimulated cyclic AMP accumulation. In contrast, PGD2 and PTA2 (a physiologically active stable analogue of thromboxane A2) had no effect on glucagonstimulated glycogenolysis or cyclic AMP accumulation. Similar studies were conducted to define the potential effects of the PGs on basal rates of hepatocyte glycogenolysis and cyclic AMP accumulation (Table 2 ). PGF2., PGB2, PGD2 and PTA2
(1 /M) all had no effect on basal rates of glycogenolysis, nor did they alter cyclic AMP content over the 0-5 min period after PG addition.
PGD2 has been previously reported to increase hepatocyte glycogenolysis [13, 22] , and has been implicated as a mediator of enhanced glycogenolysis in the perfused liver system [7, 13] . Therefore, additional studies were undertaken to characterize any potential effect of PGD2 in the hepatocyte model. Increasing the PGD2 concentration to 3 /LM did not result in any effect on basal rates of hepatocyte glycogenolysis (Table 2) . PGs are rapidly catabolized in the hepatocyte system, limiting expression of their biological activity after single additions [23] . ,-Oxidation is responsible for the rapid hepatic catabolism of PGs [24] , and, for PGE2, the addition of non-eicosanoid fatty acids such as octanoate inhibits the breakdown of PGE2 and potentiates its actions [25] . Based on these observations, the effect of PGD2 on hepatocyte glycogenolysis was also studied in the presence of 0.8 mM-octanoate (Table 3) . Again, concentrations of PGD2 as high as 3 /M had no effect on rates of glycogenolysis.
The inhibition of glucagon-stimulated glycogenolysis by PGE2 is associated with inhibition of forskolin-or glucagon-stimulated adenylate cyclase activity, which can be demonstrated by using purified liver plasma membranes [26] . PGD2, PGF2. and PGB2
were all without effect on basal adenylate cyclase activity in liver plasma membranes ( cyclase activity, whereas PGD2 had no effect (Table 4) . Hormone stimulation of hepatocyte glycogenolysis can occur independently of changes in cyclic AMP content through an increase in the cytosolic Ca2+ concentration [27] . Phenylephrine, an a-adrenergic agonist, stimulates glycogenolysis through this signal-transduction system [27] . PGE2 inhibited phenylephrinestimulated glycogenolysis in the hepatocyte system by 50%, whereas PGF2a) PGD2 and PTA2 had no effect (Table 5 ).
To clarify further the role of the hepatocyte with respect to PG-related responses in the perfused liver, the potential for arachidonic acid to mimic the action of PGs was studied in the hepatocyte system. Arachidonic acid (8.8 /M) had no effect on glucagon-stimulated hepatocyte glycogenolysis (Table 6 ). Incubations done in the presence of arachidonic acid (8.8 gM) and ibuprofen (8 FM) demonstrated rates of glucagon-stimulated glycogenolysis that were not different from incubations with either no additions (control) or arachidonic acid alone. DISCUSSION PGs modulate glucose and lipid metabolism in a variety of liver systems in vitro [1] [2] [3] [4] [5] [6] [7] [8] [9] 13, 14, 19, 22] . Apparently contradictory conclusions have been made as to PG effects on glucose metabolism, based on observations using isolated hepatocytes and perfused liver systems. This may be in part due to the presence of non-hepatocyte cell types in the perfused liver which can respond to PGs in the perfusate, and thus cause secondary metabolic effects. Using the isolated rat hepatocyte model, the current studies demonstrate that PGE2,PGF2,and PGB2 inhibit hepatocyte glucagon-stimulated glycogenolysis. No PG evaluated stimulated basal rates of hepatocyte glycogenolysis.
Inhibition of glucagon-stimulated glycogenolysis by PGE2 and PGF2. is consistent with observations by several laboratories [2] [3] [4] 9] . PGE2 [22] has been reported to stimulate basal rates of hepatocyte glycogenolysis, but the magnitude of the stimulation was small compared with other glycogenolytic hormones.
Further, both PGE2 and PGF2,also inhibit glucagon-stimulated hepatocyte cyclic AMP accumulation (Table 2; refs. [2, 19, 28] ), providing support for an action to antagonize glucagon's effects.
The action ofPGE2 and PGF2,on hepatocyte glucose metabolism and cyclic AMP accumulation is abolished by pre-treatment with pertussis toxin, consistent with coupling of the PG receptors to inhibition of cyclic AMP formation [28, 29] . PGB2, although not a naturally occurring PG, also significantly inhibited glucagonstimulated glycogenolysis. Although the relevance of this observation is at present unclear, PGB2 has actions similar to PGE2 in other physiological systems [30] . PGD2 and PTA2 had no effect on glucagon-stimulated glycogenolysis. Thus the effects of PGE2,PGF2aand PGB2 were not non-specific actions of PG-like lipids. Additionally, only PGE2 inhibited hepatocyte glycogenolysis stimulated by phenylephrine, an agent that stimulates Ca2+ mobilization (Table 5 ; ref. [4] ). This structural specificity for prostaglandin inhibition of a-adrenergic stimulated glycogenolysis is the same as that observed by Okumura and colleagues [29] . The activities of PGE2 and PGF2.thus are as modulators of hormone-stimulated glycogenolysis.
PG effects on glucagon-stimulated glycogenolysis are consistent with inhibition of hormone-stimulated adenylate cyclase Vol. 267 activity, and this effect has been previously directly demonstrated for PGE2 [26] . In the present studies PGF2a and PGB2 also inhibited forskolin-stimulated adenylate cyclase activity in plasma membranes, whereas PGD2 was without effect. This structural specificity parallels the actions of these PGs in the intact hepatocyte, and further supports the conclusions that PGE2 and PGF2 , but not PGD2, directly influence hepatocyte function. The maximal inhibition of forskolin-stimulated adenylate cyclase caused by PGE2, PGF2,or PGB2 was similar to that induced by guanosine 5'-[fiy-imido]triphosphate (Table 4 ).
This suggests that N1 (the guanine nucleotide-binding protein responsible for inhibition of adenylate cyclase) may limit maximal adenylate cyclase inhibition, and is consistent with the incomplete inhibition of glucagon-stimulated glycogenolysis and cyclic AMP accumulation observed in the intract hepatocytes.
No stimulation of hepatocyte basal rates of glycogenolysis or cyclic AMP content were observed with PGF2a,PGB2, PGD2, or PTA2. Previous studies have reported a stimulation of glycogenolysis by PGD2 in isolated hepatocytes [13, 31] . The basis for these discrepant observations is unknown. Attempts to potentiate the action of PGD2 by inhibiting its catabolism with octanoate also failed to demonstrate any stimulation of glycogenolysis by the eicosanoid. An animal-strain difference in PG action may exist, as all reported findings of a glycogenolytic action of PGD2 utilized Wistar rats [13, 31, 32] , whereas the present studies were performed with Sprague-Dawley rats. An important contribution of the work with the perfused liver model has been the demonstration that various hormones, drugs and other components induce hepatic PG synthesis [13, 14, 31] . Studies using purified preparations of hepatocytes, Kupffer cells and hepatic endothelial cells demonstrate that hepatocytes have a very limited capacity for prostaglandin biosynthesis [33] . Functional studies also support the conclusion that endogenous PG production by hepatocytes is quantitatively insignificant. Inhibition of any endogenous PG synthesis with non-steroidal anti-inflammatory drugs has no effect on rates of hepatocyte glycogenolysis [34] . Similarly, exogenous arachidonic acid could not reproduce the action of exogenous PGs in the hepatocyte system (Table 6) . Additionally, studies with a stable-isotopelabelled prostanoid showed no change in label specific radioactivity after addition to hepatocyte incubations [35] , demonstrating directly that no endogenous prostanoid (or metabolites) was present in the hepatocyte incubation.
Eicosanoids play a role in the integrated regulation of hepatic metabolism. In the intact organ, several cell types contribute to the generation of PGs and the response to PGs that ultimately results in altered hepatocyte metabolism. The present studies provide evidence that PGE2 and PGF2, act directly on the hepatocyte to antagonize glucagon action and glucagonstimulated glycogenolysis, whereas no PG tested stimulated glycogen breakdown. Further studies are needed to elucidate the importance of these observations in the physiological regulation of liver glucose and lipid metabolism.
